Discontinuing GLP-1 Therapy Linked to Doubled Cardiovascular Risk in Diabetes Patients
Stopping GLP-1 medication significantly increases the risk of heart attack, stroke, and mortality.
1Increased Cardiovascular Danger
Patients with type 2 diabetes who discontinue GLP-1 receptor agonist treatment face a doubled risk of heart attack, stroke, or death. Data indicates four events per 100 people annually for those who stop, versus two per 100 for those who continue. This study highlights the critical importance of treatment adherence.
2Study Scope and Methodology
Researchers analyzed electronic medical records from over 300 Italian diabetes clinics covering more than 80,000 patients. The study tracked individuals who initiated GLP-1 therapy between 2004 and 2024. Participants who continued treatment maintained their regimen for nearly three years, while those who discontinued averaged just over one year of usage.
3Impact of Obesity Levels
The cardiovascular risk increase varies significantly based on patient weight profiles. Individuals with obesity, defined as a body mass index above 30, experienced a 127% higher risk after stopping medication. In contrast, patients without obesity showed a 61% increase in risk, suggesting that weight status influences the severity of post-treatment outcomes.
4Limitations of Observational Research
As an observational study, these findings cannot definitively prove that stopping GLP-1 drugs directly causes cardiovascular events. It remains unclear if discontinuation is a primary driver of risk or if patients who stop treatment were already experiencing declining health. Further research is required to establish a direct causal mechanism for these findings.
5Unexplained Risk Factors
Interestingly, weight, blood sugar, and blood pressure levels showed only minor changes after patients stopped their medication. Researchers noted no significant differences in these metrics between those who suffered cardiac events and those who did not. This implies that traditional cardiometabolic markers may not fully explain the observed increase in risk.
6Evolution of GLP-1 Medications
The study primarily focused on earlier-generation GLP-1 treatments. Semaglutide represented only a minor fraction of the analyzed data, and newer drugs like tirzepatide were excluded entirely as they entered the Italian market after the study period. Consequently, the findings reflect long-term usage patterns of older, established medications within the diabetes community.
7Common Reasons for Discontinuation
Despite proven health benefits, many patients stop GLP-1 therapy within the first year of treatment. Reported barriers include gastrointestinal side effects, high financial costs, and perceived lack of efficacy. Additionally, some patients express concerns regarding rare side effects, leading them to discontinue the regimen before achieving long-term cardiovascular protection goals.
8Clinical Implications for Patients
For patients with type 2 diabetes and no established cardiovascular disease, long-term GLP-1 use appears vital for maintaining health. The findings suggest that consistent therapy is necessary to sustain the protective benefits against heart-related complications. Clinicians should emphasize these risks when discussing the potential discontinuation of prescribed diabetes management plans.